▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Novo Nordisk (NYSE: NVO)

$75.26

(0.8%)

$0.63

Price as of June 9, 2025, 1:49 p.m. ET

Novo Nordisk Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
NVO	-46.51%	+151.20%	+20.20%	+64,825%
S&P	+12.09%	+87.87%	+13.43%	+4,541%

Novo Nordisk Company Info

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

News & Analysis

The Fool has written over 500 articles on Novo Nordisk.

Featured Article

The Largest Healthcare Companies by Market Cap in June 2025

Eli Lilly, Johnson & Johnson, and AbbVie command the healthcare sector.

Lyle Daly | Jun 8, 2025

Featured Article

Novo Nordisk Stock: Is It Still a Smart Buy?

Eric Volkman | Jun 6, 2025

2 Top Stocks to Buy With Less Than $100

Prosper Junior Bakiny | May 30, 2025

2 Beaten-Down Stocks to Buy on the Dip

Prosper Junior Bakiny | May 30, 2025

Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?

Justin Pope | May 28, 2025

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.

Why Novo Nordisk Stock Just Popped

Rich Smith | May 27, 2025

President Trump has good news for Novo Nordisk investors, and more may be on the way.

Why Novo Nordisk Stock Popped on Tuesday

Rich Smith | May 20, 2025

If you can't beat Novo Nordisk, maybe you should join 'em?

2 Fantastic Beaten-Down Growth Stocks Down 40% and 45% to Buy

Neil Rozenbaum | May 20, 2025

These two stocks are poised for near-term and long-term upside.

Valuation

Podcast Episodes

Diabetes Deep-Dive: What Investors Need to Know About This Devastating Disease

Explaining diabetes, its various treatment options, and what the future may have in store for this disease.

Todd Campbell and Gaby Lapera | Jun 18, 2016

Earnings Transcripts

Novo Nordisk (NVO) Q4 2024 Earnings Call Transcript

NVO earnings call for the period ending December 31, 2024.

Motley Fool Transcribing | Feb 5, 2025

Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript

NVO earnings call for the period ending September 30, 2024.

Motley Fool Transcribing | Nov 6, 2024

Novo Nordisk (NVO) Q2 2024 Earnings Call Transcript

NVO earnings call for the period ending June 30, 2024.

Motley Fool Transcribing | Aug 7, 2024

Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript

NVO earnings call for the period ending March 31, 2024.

Motley Fool Transcribing | May 2, 2024

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services